scholarly journals Treatment of Chronic Obstructive Pulmonary Disease by Dual Bronchodilation with Coformulation of Indacaterol/Glycopyrronium

Pharmacology ◽  
2014 ◽  
Vol 94 (5-6) ◽  
pp. 249-258 ◽  
Author(s):  
Girolamo Pelaia ◽  
Rosario Maselli ◽  
Maria Gabriella Matera
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Dual Bronchodilation

scholarly journals The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease

2020 ◽  
Vol 14 ◽  
pp. 175346662092680
Author(s):  
Kyriakos Souliotis ◽  
Luís Silva Miguel ◽  
Georgios Hillas ◽  
Margarida Borges ◽  
Giannis Papageorgiou ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Budget Impact ◽  
Healthcare Resource ◽  
Cost Savings ◽  
Base Case ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Dual Bronchodilation ◽  
Long Acting

Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018 recommendations support maintenance treatment with long-acting bronchodilators in most symptomatic patients with chronic obstructive pulmonary disease (COPD). While restricting the overuse of inhaled corticosteroids (ICS) may influence healthcare utilization required to treat inadvertent respiratory (exacerbations and pneumonia) and diabetes-related events, it may also change the total medication cost. This analysis was performed to estimate the 5-year budget impact of switching from ICS-containing treatment combinations to dual bronchodilation, in line with the recommendations. Methods: The model quantified the budget impact of treatment and healthcare resource utilization when COPD patients were anticipated to switch from ICS-containing treatments to dual bronchodilation. Three switch scenarios were calculated with increasing proportions of patients on dual long-acting bronchodilators, to the detriment of ICS-containing double and triple combinations. Clinical and cost input data were based on results from clinical trials and Greek and Portuguese healthcare cost databases. Results: Healthcare resource use to manage exacerbations, pneumonia and diabetes-related events were projected to increase between 2019 and 2023 in parallel with the growing COPD patient population and associated costs were estimated at 52–57% of the total disease cost in the Greek and Portuguese base case scenarios. Total cost savings between 21 and 112 million EUR were projected when the proportion of patients on double and triple ICS-containing treatments was gradually reduced to 50% in scenario A, 20% in scenario B and 7% in scenario C. Sensitivity analyses showed that none of the model assumptions had a major impact on the projected savings. Conclusion: The alignment of COPD treatment with current recommendations may bring clinical benefits to patients, without substantial cost increases and even cost savings for payers. The reviews of this paper are available via the supplemental material section.

scholarly journals New opportunities of dual bronchodilation therapy for patients with chronic obstructive pulmonary disease

2019 ◽  
Vol 91 (3) ◽  
pp. 76-85
Author(s):  
S N Avdeev ◽  
N V Trushenko
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Fixed Combination ◽  
Chronic Obstructive ◽  
Clinical Effects ◽  
Dosing Regimen ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Dual Bronchodilation ◽  
Long Acting

Currently, combinations of long-acting beta2-agonists and long-acting anticholinergics are considered as the basic therapy for majority of patients with chronic obstructive pulmonary disease (COPD). These combinations have different pharmacological characteristics and delivery devices that provides different clinical effects and new opportunities for personalized treatment of COPD. Aclidinium/formoterol fixed combination differs from other dual bronchodilators by twice-daily dosing regimen, good safety profile and a specific delivery system. Recent information on clinical efficacy and safety of aclidinium/formoterol combination in COPD patients is given in this article.

Sign in / Sign up

Export Citation Format

Share Document